SCHEMBL2829280

SCHEMBL2829280

Cc1onc(-c2ccccc2)c1C(=O)c1cc2cccc(OCc3ccncc3)c2o1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIM1 P11309 1/20 0.46
PIM2 Q9P1W9 1/20 0.46
SMN1; SMN2 Q16637 3/20 0.45
MAPK1 P28482 1/20 0.45
ALDH1A1 P00352 4/20 0.44
KMT2A Q03164 4/20 0.44
KDM4E B2RXH2 2/20 0.44
HPGD P15428 2/20 0.44
HSD17B10 Q99714 1/20 0.44
GAA P10253 3/20 0.43
HTT P42858 3/20 0.43
MEN1 O00255 3/20 0.43
NPC1 O15118 2/20 0.43
RAB9A P51151 1/20 0.43
TSHR P16473 3/20 0.42
LMNA P02545 2/20 0.42
POLB P06746 2/20 0.42
MAPT P10636 1/20 0.42
NPSR1 Q6W5P4 1/20 0.42
TDP1 Q9NUW8 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2827476 0.94 KMT2A (0.46) SMN1; SMN2MAPK1ALDH1A1KMT2AHPGD
SCHEMBL2829309 0.92 PIM1 (0.48) PIM1PIM2SMN1; SMN2MAPK1ALDH1A1
SCHEMBL2827876 0.91 POLB (0.49) SMN1; SMN2ALDH1A1KMT2AKDM4EHPGD
SCHEMBL2829178 0.90 ALDH1A1 (0.52) SMN1; SMN2ALDH1A1KMT2AKDM4EHPGD
SCHEMBL2828886 0.88 SMN1; SMN2 (0.51) SMN1; SMN2ALDH1A1KMT2AKDM4EHPGD
SCHEMBL2827742 0.88 GAA (0.50) SMN1; SMN2MAPK1ALDH1A1KMT2AKDM4E
SCHEMBL2829677 0.88 POLB (0.51) SMN1; SMN2ALDH1A1KMT2AKDM4EHPGD
SCHEMBL2825500 0.86 ALDH1A1 (0.48) SMN1; SMN2MAPK1ALDH1A1KMT2AHPGD
SCHEMBL2827849 0.85 KMT2A (0.61) SMN1; SMN2ALDH1A1KMT2AKDM4EHPGD
SCHEMBL2830575 0.84 NPC1 (0.40) SMN1; SMN2ALDH1A1KMT2AKDM4EHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1948648-B1 3-ARYL-ISOXAZOLE-4-CARBONYL-BENZOFURANE DERIVATIVES HOFFMANN LA ROCHE (CH) 2010-05-05 EP claimed
EP-1948648-A2 3-ARYL-ISOXAZOLE-4-CARBONYL-BENZOFURAN DERIVATIVES F.HOFFMANN-LA ROCHE AG (CH) 2008-07-30 EP claimed
US-7388025-B2 3-aryl-isoxazole-4-carbonyl-benzofuran derivatives HOFFMAN-LA ROCHE INC. (US) 2008-06-17 US claimed
WO-2007054444-A2 3-ARYL-ISOXAZOLE-4-CARBONYL-BENZOFURAN DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2007-05-18 WO claimed
US-20070105922-A1 3-aryl-isoxazole-4-carbonyl-indole derivatives F. HOFFMANN-LA ROCHE AG (CH) 2007-05-10 US claimed
EP-1948648-B1 3-ARYL-ISOXAZOLE-4-CARBONYL-BENZOFURANE DERIVATIVES HOFFMANN LA ROCHE (CH) 2010-05-05 EP disclosed
EP-1948648-A2 3-ARYL-ISOXAZOLE-4-CARBONYL-BENZOFURAN DERIVATIVES F.HOFFMANN-LA ROCHE AG (CH) 2008-07-30 EP disclosed
US-7388025-B2 3-aryl-isoxazole-4-carbonyl-benzofuran derivatives HOFFMAN-LA ROCHE INC. (US) 2008-06-17 US disclosed
WO-2007054444-A2 3-ARYL-ISOXAZOLE-4-CARBONYL-BENZOFURAN DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2007-05-18 WO disclosed
US-20070105922-A1 3-aryl-isoxazole-4-carbonyl-indole derivatives F. HOFFMANN-LA ROCHE AG (CH) 2007-05-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070105922-A1 3-aryl-isoxazole-4-carbonyl-indole derivatives GABRA5, GABRA4, GABRA3 PIM1 2319/4885PIM2 2415/4885SMN1; SMN2 2521/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.